Goldman Sachs downgraded Apellis (APLS) to Neutral from Buy with a $36 price target The firm’s key opinion leader discussions indicate the actual number of geographic atrophy patients that physicians would treat with Apellis’ lead drug, Syfovre or the competitor, Astellas’ Izervay is smaller than anticipated. Goldman sees a slow progressing launch on the forward, saying a lack of clear functional benefit data limits broader uptake. Together these point to a more conservative commercial outlook for Apellis, the analyst tells investors in a research note.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Biotech Alert: Searches spiking for these stocks today
- Ulta Beauty downgraded, Palo Alto upgraded: Wall Street’s top analyst calls
- Apellis initiated with an Equal Weight at Morgan Stanley
- Walmart higher, Lowe’s lower after earnings: Morning Buzz
- Astellas receives Complete Response Letter for Izervay, Apellis rallies